BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.

Diehl, Volker; Franklin, Jeremy; Hasenclever, Dirk; Tesch, Hans; Pfreundschuh, Michael; Lathan, B.; Paulus, U.; Sieber, M.; Rueffer, Jens Ulrich; Sextro, M; Engert, Andreas; Wolf, Jürgen; Hermann, Róbert; Holmer, L; Stappert-Jahn, U; Winnerlein-Trump, E; Wulf, Gerburg M.; Krause, Stefan W.; Glunz, A.; Kalle, K. von; Bischoff, Helge; Haedicke, C; Duêhmke, E.; Georgii, A.; Loeffler, Markus

doi:10.1200/jco.1998.16.12.3810

Cited by 176 publications

(103 citation statements)

References 25 publications

Supporting

Mentioning

100

Contrasting

Unclassified

Order By: Relevance

“…The intensive regimen of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, and prednisone (BEACOP) has been proposed as a very effective induction treatment for patients with high-risk HL. 46 However, it has not been demonstrated that salvage regimens are as feasible or as effective after BEACOP as they are after less intensive, conventional regimens. To address this issue, a randomized trial of ABVD compared with BEACOP, both coupled with an HDS-like salvage program, in patients who do not respond to induction therapy is underway at IIL centers.…”

Section: Discussionmentioning

confidence: 99%

High‐dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma

Tarella

Cuttica

Vitolo

et al. 2003

Cancer

View full text Add to dashboard Cite

BACKGROUNDThe objective of the current study was to evaluate in a multicenter setting the feasibility and efficacy of a high‐dose sequential (HDS) chemotherapy regimen that combined intensive debulking and high‐dose therapy (HDT) with peripheral blood progenitor cell (PBPC) autografting in patients with refractory or recurrent Hodgkin lymphoma (HL).METHODSData were collected from 102 patients with HL who were treated with the HDS regimen at 14 centers associated with the Intergruppo Italiano Linfomi. Twenty‐four patients had primary refractory HL, 59 patients had their first recurrence of HL (within 1 year in 32 patients and > 1 year in 27 patients), and 19 patients had multiple disease recurrences. The HDS regimen included the sequential delivery of high‐dose (hd) cyclophosphamide with PBPC harvesting, methotrexate, etoposide, then HDT (usually hd mitoxantrone plus L‐phenylalanine mustard) with PBPC autografting. In addition, radiotherapy was delivered to 36 patients at sites of bulky or persistent disease.RESULTSNinety‐two patients (90%) completed the HDS program. There were five toxic deaths (treatment‐related mortality rate, 4.9%) and six secondary malignan cies (five patients developed myelodysplastic syndrome/acute myelogenous leukemia, and one patient developed colorectal carcinoma). At a median follow‐up of 5 years, the 5‐year overall survival (OS) and event‐free survival (EFS) projections were 64% (95% confidence interval [95% CI], 54–74%) and 53% (95% CI, 43–63%), respectively. Patients with their first recurrence had the most favorable outcome, with 5‐year OS and EFS projections of 77% (95% CI, 66–88%) and 63% (95% CI, 50–76%), respectively. There were no significant differences between patients with early first recurrence and late first recurrence. The poorest outcome was observed in patients with refractory HL, with 5‐year OS and EFS projections of 36% (95% CI, 16–55%) and 33% (95% CI, 14–52%), respectively. Patients who received HDS chemotherapy after multiple recurrences had an intermediate outcome. Multivariate analysis showed that refractory disease and systemic symptoms at the time of initial presentation were associated significantly associated with poor OS and EFS.CONCLUSIONSThe use of HDS chemotherapy for patients with refractory and/or recurrent HL is feasible at the multicenter level. The combination of intensive debulking and HDT with PBPC autografting offers a good chance of prolonged disease free survival for patients with their first recurrence of HL. Cancer 2003;97:2748–59. © 2003 American Cancer Society.DOI 10.1002/cncr.11414

show abstract

Section: Discussionmentioning

confidence: 99%

High‐dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma

Tarella

Cuttica

Vitolo

et al. 2003

Cancer

View full text Add to dashboard Cite

show abstract

“…29,33 Very few HL patients with advanced disease and high-risk features received BEACOPP chemotherapy (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) during the study period. 2,34 Combined modality treatment for patients with limited-stage disease became increasingly common during the 1980s. 35 Irradiation for previously bulky disease in patients with stage III-IV disease was also widespread during the 1980s and 1990s.…”

mentioning

confidence: 99%

Progress in Hodgkin lymphoma: a population-based study on patients diagnosed in Sweden from 1973-2009

Sjøberg

Halthur

Kristinsson

et al. 2012

Blood

View full text Add to dashboard Cite

In recent decades, attention has focused on reducing long-term, treatment-related morbidity and mortality in Hodgkin lymphoma (HL). In the present study, we looked for trends in relative survival for all patients diagnosed with HL in Sweden from 1973-2009 (N ‫؍‬ 6949; 3985 men and 2964 women; median age, 45 years) and followed up for death until the end of 2010. Patients were categorized into 6 age groups and 5 calendar periods (1973-1979, 1980-1986, 1987-1994, 1994-2000, and 2001-2009 IntroductionOver the past 40 years, major advances have been made in the management of patients with Hodgkin lymphoma (HL). These include the introduction of more accurate radiotherapy, effective multiagent chemotherapy, immunotherapy, improved staging procedures, and important developments in supportive measures for myelosuppression and infectious and other complications. 1 Therefore, HL has gone from being an invariably fatal disorder to one of the few malignancies that are now highly curable. This is particularly true for patients with early-stage disease, but today disease control rates also exceed 70% in patients presenting with high-risk features. 2 This therapeutic success has unfortunately been darkened by elevated risks of secondary primary cancers, cardiovascular disease (CVD), cerebrovascular disease, and infections in longterm HL survivors. [3][4][5][6][7][8][9][10][11][12][13][14][15][16] CVD has been reported to be the most important cause of excess mortality after HL and second malignancies. [10][11][13][14] During the last 2-3 decades, treatment strategies have been and are being adapted based on increased knowledge of treatment-related morbidity and mortality. Awaiting novel and less toxic targeted therapies of HL, the largest potential for improving survival and healthrelated quality of life in long-term survivors 17 is by reducing the excess morbidity and mortality from causes other than HL. To evaluate progress in long-term outcome, we studied patient survival among all 6949 HL patients diagnosed in Sweden between 1973 and 2009 and followed up for death to the end of 2010. Our aim was to assess trends in patient survival and long-term excess mortality in the entire population during this 37-year period starting when curative treatment principles were well-established. Methods Central registers and patientsInformation regarding patients diagnosed with a malignant disorder in Sweden is reported to a population-based nationwide Swedish Cancer Register that was established in 1958. The register contains information on diagnosis, sex, date of birth, date of diagnosis, and the hospital where the diagnosis was made, 18-19 but does not contain detailed clinical information such as symptoms, routine laboratory tests, treatment, or comorbidities.In Sweden, every physician and pathologist/cytologist is obliged by law to report each occurrence of cancer to the registry. All deaths are recorded in the nationwide causes of death register. Each person in Sweden is given a unique national registration number used to index a...

show abstract

“…[2][3][4][5][6][7][8][9][10][11][12][13][14][15][16] Once patients relapse after initial therapy, however, conventionaldose chemotherapy regimens usually fail to provide durable complete remissions. [17][18][19][20][21][22][23][24] In the series with the longest follow-up, Longo and associates 17 reported that although 93% of relapsing patients could be re-induced into a second complete remission, only 17% of these remissions were durable.…”

mentioning

confidence: 99%

Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR)

Lazarus

Loberiza

Zhang

et al. 2001

Bone Marrow Transplant

109

View full text Add to dashboard Cite

Summary:Although patients with relapsed Hodgkin's disease have a poor prognosis with conventional therapies, high-dose chemotherapy and autologous hematopoietic stem cell transplantation (autotransplantation) may provide long-term progression-free survival. We reviewed data from the Autologous Blood and Marrow Transplant Registry (ABMTR) to determine relapse, disease-free survival, overall survival, and prognostic factors in this group of patients. Detailed records from the ABMTR on 414 patients with Hodgkin's disease in first relapse (n = 295) or second complete remission (CR) (n = 119) receiving an autotransplant from 1989 to 1995 were reviewed. Median age was 29 (range, 7-64) years. Median time from diagnosis to relapse was 18 (range, 6-219) months; median time from relapse to transplant was 5 (range, Ͻ1-215) months. Most patients received high-dose chemotherapy without total body irradiation for conditioning (n = 370). The most frequently used high-dose regimen was cyclophosphamide, BCNU, VP-16 (CBV) (n = 240). The graft consisted of bone marrow (n = 246), blood stem cells (n = 112), or both (n = 56).

show abstract

BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.

Abstract: Combined with local irradiation, BEACOPP in one or both variants shows superior disease control compared with COPP/ABVD, with acceptable acute toxicity. Further follow-up is required to assess the effect of dosage and the effect on survival and late toxicities.

Cited by 176 publications

References 25 publications

High‐dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma

High‐dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma

Progress in Hodgkin lymphoma: a population-based study on patients diagnosed in Sweden from 1973-2009

Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR)

Contact Info

Product

Resources

About